Rocket Pharmaceuticals, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Rocket Pharmaceuticals, Inc. (RCKT) reported Restructuring and Related Cost, Number of Positions Eliminated of 70 Employees for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2026-03-31 was 70.00 Employees.
- Rocket Pharmaceuticals, Inc. restructuring and related cost, number of positions eliminated for fiscal 2025 was 70.00 Employees.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 6 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|---|---|
| 2026-06-30 | 70.00 Employees 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 70.00 Employees 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 70.00 Employees 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 70.00 Employees 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 80.00 Employees 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |